At the same time, new tuneable BTK irreversible inhibitors such as Rilzabrutinib, or reversible inhibitors able to bind to an inactive non-phosphorylated BTK conformation such as CGI-1746, could represent a promising class of compounds with reduced side effects compared to classical irreversible compounds, such as being able to treat hematological cancers that are Ibrutinib-resistant, as well as chronic pathologies such as autoimmune disorders (i.e., RA, SLE, and cGVHD). This evidence concerns the gene BTK and systemic lupus erythematosus.